SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development

(Moderate)

(Very Positive)

Rhea-AI Summary

Allergan Aesthetics (NYSE: ABBV), through its SkinMedica brand, announced an expanded commitment to regenerative science on July 14, 2026. The company launched the SkinMedica Regenerative Science Advisory Board, bringing together physicians, clinicians, and skin health experts to foster scientific dialogue, share clinical best practices, and connect breakthrough research with everyday patient care.

According to Allergan Aesthetics, SkinMedica also expanded its Irvine, California R&D lab to more than double its previous footprint, adding advanced pre-clinical research capabilities, sophisticated imaging, and AI- and machine learning–enabled discovery. In parallel, SkinMedica introduced its first in-practice flagship retail experiences at select U.S. medical aesthetics practices, including locations in Rapid City, South Dakota, and Scottsdale, Arizona, with more sites planned in 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Market Context

Investors may watch how these skincare investments complement larger immunology and oncology catalys...

Analysis

Investors may watch how these skincare investments complement larger immunology and oncology catalysts without introducing dilution risk.

Key Figures

Brand history: more than 25 years Flagship locations: first flagship locations Year: 2026 +1 more

4 metrics

Brand history more than 25 years SkinMedica advancing science-backed skincare solutions

Flagship locations first flagship locations Initial SkinMedica in-practice flagship retail experiences launched

Year 2026 Additional flagship locations planned across key U.S. markets throughout 2026

Facility size change more than double SkinMedica R&D facility footprint now more than double its previous size

Historical Context

5 past events · Latest: Jul 06 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 06	EU approval	Positive	-2.4%	European Commission approved TEPKINLY combo for relapsed or refractory follicular lymphoma.
Jun 29	Phase 3 data	Positive	-1.1%	Positive Phase 3 epcoritamab plus lenalidomide results in diffuse large B-cell lymphoma.
Jun 29	CHMP opinion	Positive	+0.4%	Positive CHMP opinion for RINVOQ in severe alopecia areata in the EU.
Jun 29	CHMP opinion	Positive	+0.4%	Positive CHMP opinion for RINVOQ in non-segmental vitiligo in the EU.
Jun 26	FDA approval	Positive	+0.4%	FDA approved SKYRIZI for pediatric psoriatic disease, expanding the label to children.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent AbbVie news has typically produced modest single-day moves, with some positive clinical and regulatory milestones met by muted or even negative price reactions.

Key Terms

r&d, pre-clinical research, artificial intelligence, machine learning

4 terms

r&d technical

"Expands its state-of-the-art research and development (R&D) facility"

Research and development (R&D) is the work a company does to discover new products, improve existing ones, or develop better ways of making things — like a kitchen testing recipes to create a hit dish. For investors it matters because R&D is where future sales and competitive advantages are born, but it also uses cash and carries risk, so R&D spending and outcomes signal a company’s growth potential and uncertainty.

pre-clinical research medical

"The state-of-the-art lab supports a broad range of pre-clinical research"

Research done before testing a new drug, device, or therapy in humans that uses lab experiments, computer models, and animal studies to learn how it works, how it is absorbed and broken down, and whether it has obvious safety problems. Investors care because pre-clinical results shape the chances, timeline, and cost of moving a candidate into human trials—think of it as the prototype and safety checks before building a product.

artificial intelligence technical

"SkinMedica is also leveraging artificial intelligence and machine learning"

Artificial intelligence is the ability of computers and machines to perform tasks that typically require human thinking, such as understanding language, recognizing patterns, or making decisions. For investors, it matters because AI can enhance efficiency, uncover new insights, and enable smarter strategies, potentially impacting the value and performance of companies that develop or utilize this technology.

machine learning technical

"leveraging artificial intelligence and machine learning to identify novel biological targets"

Machine learning is a set of computer programs that learn patterns from large amounts of data and improve their predictions or decisions over time, like a recipe that gets better each time it’s adjusted based on taste tests. For investors it matters because these systems can speed up analysis, spot trends or risks humans might miss, automate routine work, and potentially create competitive advantages or cost savings that affect a company’s performance.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

07/14/2026 - 08:05 AM

SkinMedica^® launches Regenerative Science Advisory Board to shape future innovation
Expands its state-of-the-art research and development (R&D) facility to support the next generation of science-led innovation
Debuts flagship retail experiences designed to support practice and patients' needs

IRVINE, Calif., July 14, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, is proud to announce SkinMedica's expanded commitment to regenerative science, advancing investments that will support innovation, research, clinical insight, and patient experience.

"Stemming from its origins in wound-healing research, SkinMedica was founded on the principles of regenerative skincare," said Glen Curran, senior vice president, Allergan Aesthetics. "For more than 25 years, the brand has consistently advanced science-backed solutions, and today we're excited to introduce initiatives that continue to reinforce its mission to support skin health from cell to surface."

SkinMedica's Regenerative Science Advisory Board

SkinMedica has launched the Regenerative Science Advisory Board, a collective of leading physicians, clinicians, and skin health experts from across the country. Through in-person collaboration, virtual consultations, and curated content across SkinMedica-owned platforms, the advisory board will foster scientific dialogue, share clinical best practices, and help bridge breakthrough research with everyday patient care.

"Scientific innovation is most impactful when it is informed by the clinicians and experts who bring it to life every day," said Curran. "We're honored to welcome this distinguished group of thought leaders to the SkinMedica Regenerative Science Advisory Board. Their expertise and real-world perspective will help advance scientific education, strengthen collaboration across the aesthetic community, inform future conversations around skin longevity and innovation; while ensuring we continue to translate breakthrough science into meaningful solutions for providers and patients."

State-of-the-Art R&D Facility

The advisory board reinforces Allergan Aesthetics' leadership in professional-grade skincare and complements its continued investment in SkinMedica innovation, including the recent expansion of the SkinMedica R&D lab in Irvine, Calif.

The state-of-the-art lab supports a broad range of pre-clinical research and sophisticated imaging technologies that provide deeper insight into skin biology. SkinMedica is also leveraging artificial intelligence and machine learning to identify novel biological targets, accelerate ingredient discovery, and advance understanding of the cellular drivers of skin longevity to solve for unmet skin concerns.

"The expanded SkinMedica R&D Lab reflects our commitment to advancing the future of skincare through scientific excellence, strategic collaboration, and emerging technologies," said Prithwiraj Maitra, Ph.D., vice president, global skincare R&D, Allergan Aesthetics. "By integrating advanced research capabilities with AI-enabled discovery and clinical expertise, we are accelerating our ability to transform breakthrough science into meaningful innovations that deliver for patients and providers."

Now more than double its previous footprint, the enhanced facility brings together formulation scientists, biological researchers, and clinical experts under one roof to streamline, strengthen, and modernize the development process of next-generation, regenerative skincare.

Educational Shopping Experience at SkinMedica Flagship Stores

Beyond advancing brand education and product development, SkinMedica has also launched its first in-practice flagship retail experience at select, highly regarded medical aesthetics practices nationwide. Designed to extend the physician-guided skincare journey beyond the treatment room, these dedicated spaces provide an immersive environment where patients can test SkinMedica products, learn about the clinical science behind the brand, and further explore the personalized regimens recommended by their provider.

The first flagship locations include Lycia Thornburg, M.D. Dermatology in Rapid City, S.D. and The Skin Clinic in Scottsdale, Ariz., with additional locations planned to open across key U.S. markets throughout 2026.

To learn more about the SkinMedica range of products, visit SkinMedica.com, and follow along on Instagram @SkinMedica for more from the SkinMedica Regenerative Science Advisory Board and flagship shopping experiences.

About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com.

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

SkinMedica^® Important Information

Most SkinMedica^® products are intended to meet the FDA's definition of a cosmetic product, an article applied to the human body to cleanse, beautify, promote attractiveness, and alter appearances. These SkinMedica^® products are not intended to be drug products that diagnose, treat, cure, or prevent any disease or condition. These products have not been approved by the FDA and the statements have not been evaluated by the FDA.

Investors:
Liz Shea
Liz.Shea@AbbVie.com
(847) 935-2211

Media:
Ember Garrett
Ember.Garrett@allergan.com
(714) 246-3525

View original content:https://www.prnewswire.com/news-releases/skinmedica-deepens-commitment-to-regenerative-science-with-continued-investment-in-research-and-development-302824504.html

SOURCE AbbVie

FAQ

What did AbbVie’s SkinMedica announce on July 14, 2026 (ABBV)?

SkinMedica announced a broader commitment to regenerative science, including a new advisory board, expanded R&D lab, and flagship retail experiences. According to Allergan Aesthetics, these initiatives aim to link advanced research with clinical practice and patient-focused skincare education.

What is the SkinMedica Regenerative Science Advisory Board and why was it created?

The SkinMedica Regenerative Science Advisory Board is a group of physicians, clinicians, and skin health experts formed to guide innovation. According to Allergan Aesthetics, it will foster scientific dialogue, share best practices, and help translate breakthrough research into everyday patient care.

How is SkinMedica expanding its R&D lab in Irvine and what technologies are involved?

SkinMedica has more than doubled its Irvine R&D lab footprint, adding advanced pre-clinical research and imaging capabilities. According to Allergan Aesthetics, the lab also uses artificial intelligence and machine learning to identify biological targets and support regenerative skincare development.

How is artificial intelligence being used in SkinMedica’s regenerative skincare research?

SkinMedica is using artificial intelligence and machine learning to identify novel biological targets and speed ingredient discovery. According to Allergan Aesthetics, these tools help deepen understanding of cellular drivers of skin longevity and address unmet skin concerns in product development.

Where are the first SkinMedica flagship retail experiences located and when will more open?

The first SkinMedica flagship retail experiences are at Lycia Thornburg, M.D. Dermatology in Rapid City, South Dakota, and The Skin Clinic in Scottsdale, Arizona. According to Allergan Aesthetics, additional flagship locations are planned in key U.S. markets throughout 2026.

What is the goal of SkinMedica’s in-practice flagship shopping experiences for patients?

The flagship experiences are designed to extend the physician-guided skincare journey beyond the treatment room. According to Allergan Aesthetics, they offer immersive spaces for testing products, learning about the brand’s clinical science, and exploring personalized regimens recommended by providers.

How does SkinMedica’s expanded R&D lab support regenerative skincare innovation for ABBV?

The expanded lab unites formulation scientists, biological researchers, and clinical experts under one roof, streamlining product development. According to Allergan Aesthetics, this integrated setup aims to turn breakthrough regenerative science into next-generation skincare solutions for patients and providers.